The Food and Drug Administration (FDA) approved moxetumomab pasudotox (Lumoxiti), a bacterial toxin–based drug, for the...
Latest Announcements
-
September 20, 2018
-
September 18, 2018NCI TTC's new start-up license program makes it easier and more financially attractive for start-ups to license a...
-
September 4, 2018The 2018 Technology Showcase featured technologies from the National Cancer Institute and the Frederick National Laboratory for...
-
March 12, 2018The Federal Laboratory Consortium (FLC) for Technology Transfer has recognized three National Cancer Institute ...
